Table 1.
Patient characteristics (n = 20)
| Age, years | 68 (64–70) |
| Sex male | 18 (90) |
| Weight, kg | 84 (69–100) |
| BSA, m2 | 1.98 (1.82–2.16) |
| BMI, kg m−2 | 28 (24–33) |
| Prior co-morbidities | |
| Hypertension | 14 (70) |
| Type 2 diabetes mellitus | 9 (45) |
| COPD | 3 (15) |
| Asthma | 2 (10) |
| Left ventricular hypertrophy | 7 (35) |
| Atrial fibrillation | 4 (20) |
| Medication prior to surgery | |
| Acetylsalicylic acid | 17 (85) |
| Clopidogrel | 1 (5) |
| Low molecular weight heparin | 7 (35) |
| Beta blocker | 15 (75) |
| Statin | 16 (80) |
| ACE inhibitor or AT II receptor inhibitor | 12 (60) |
| Long-acting nitrate | 8 (40) |
| Medical state prior to surgery | |
| Ejection fraction | |
| > 50% | 16 (80) |
| 31–50% | 2 (10) |
| 21–30% | 2 (10) |
| Coronary artery stenoses | |
| RCA | 20 (100) |
| CX | 17 (85) |
| LAD | 19 (95) |
| LM | 7 (35) |
| NYHA class | 3 (2–3) |
| Euroscore II, % | 1.43 (0.90–2.27) |
| Hemoglobin, g L−1 | 141 (130–157) |
| Thrombocytes, E9 L−1 | 255 (208–307) |
| INR | 1.0 (1.0–1.1) |
| Surgery | |
| Urgency | |
| Urgent | 10 (50) |
| Elective | 10 (50) |
| Number of bypasses | 4 (3–4) |
| Levosimendan used | 5 (25) |
| Norepinephrine max dose, microg kg−1 min−1 | 0.18 (0.12–0.44) |
| Dobutamine max dose, microg kg−1 min−1 | 2.00 (0.00–2.74) |
| I.v. nitrate used | 14 (70) |
| OR stay, min | 404 (344–440) |
| Time in ventilator, OR and ICU combined, h | 9 (8–12) |
| ICU length of stay, days | 1 (1–3) |
| Hospital length of stay, days | 9 (8–13) |
| Hospital mortality | 0 (0) |
The values given are medians with 25th and 75th percentiles, or number of patients (n) with percentages (%). BSA body surface area, BMI body mass index, RCA right coronary artery, CX circumflex artery, LAD left anterior descending artery, LM left main artery, NYHA Class New York Heart Association Classification, INR international normalized ratio, OR operating theatre, ICU intensive care unit